A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation

Although major cardiovascular events were not reduced at 1 year, this study confirms a benefit in patient-reported outcome measures.

Several recent trials demonstrate that transcatheter valve repair (TRILUMINATE; NEJM JW Cardiol Mar 6 2023 and N Engl J Med 2023; 388:1833) or replacement (TRISCEND II; NEJM JW Cardiol Nov 13 2024 and N Engl J Med 2024 Oct 30; [e-pub]) can improve quality of life for patients with severe tricuspid regurgitation (TR). To further examine the clinical benefits of valve repair for TR, researchers randomized 300 patients with severe, symptomatic TR to receive tricuspid transcatheter edge-to-edge repair (T-TEER) plus optimal medical therapy (OMT) or OMT alone (NCT04646811).

The primary clinical composite outcome score included change in New York Heart Association class, change in patient-reported global assessment, and occurrence of major cardiova…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)